Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Net Margin (2016 - 2025)

Adma Biologics (ADMA) has disclosed Net Margin for 13 consecutive years, with 43.4% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin fell 5179.0% year-over-year to 43.4%, compared with a TTM value of 30.96% through Dec 2025, down 1539.0%, and an annual FY2025 reading of 30.96%, down 1539.0% over the prior year.
  • Net Margin was 43.4% for Q4 2025 at Adma Biologics, up from 27.14% in the prior quarter.
  • Across five years, Net Margin topped out at 95.19% in Q4 2024 and bottomed at 132.7% in Q4 2022.
  • Average Net Margin over 5 years is 14.61%, with a median of 4.13% recorded in 2023.
  • The sharpest move saw Net Margin surged 15346bps in 2021, then crashed -10269bps in 2022.
  • Year by year, Net Margin stood at 30.01% in 2021, then plummeted by -342bps to 132.7% in 2022, then surged by 111bps to 14.34% in 2023, then surged by 564bps to 95.19% in 2024, then tumbled by -54bps to 43.4% in 2025.
  • Business Quant data shows Net Margin for ADMA at 43.4% in Q4 2025, 27.14% in Q3 2025, and 28.05% in Q2 2025.